Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Ozuriftamab Vedotin Alone and with Nivolumab in Advanced Solid Tumors
2022-000137-17Phase 2Completed
- Sponsor
- BioAtla
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ozuriftamab vedotin in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (2 arms), sponsored by BioAtla. Primary endpoint: Objective response rate (ORR). Started Jun 2022; status: completed.
02
Drugs
ozuriftamab vedotin
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-000137-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000137-17.